Get the Stockscreener App
8.98
2.98%
0.26
Arcutis Biotherapeutics Inc stock is traded at $8.98, with a volume of 1.36M.
It is up +2.98% in the last 24 hours and down -10.38% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$8.72
Open:
$8.59
24h Volume:
1.36M
Relative Volume:
0.70
Market Cap:
$1.05B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-1.6209
EPS:
-5.54
Net Cash Flow:
$-247.49M
1W Performance:
+4.91%
1M Performance:
-10.38%
6M Performance:
+12.25%
1Y Performance:
+268.03%
1-Day Range:
$8.45
$9.19
1-Week Range:
$8.21
$9.19
52-Week Range:
$1.76
$13.17
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
abrdn plc Boosts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 8.7% HigherHere's Why - MarketBeat
AMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Jefferies Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy Recommendation - MSN
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting - StockTitan
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis - Yahoo Finance
Health Canada approves Arcutis’ Zoryve foam for seborrheic dermatitis - World Pharmaceutical Frontiers
Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - BioSpace
SG Americas Securities LLC Reduces Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Behind the Bell: Arcutis Biotherapeutics - Nasdaq
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2%Here's What Happened - MarketBeat
Arcutis Biotherapeutics receives Health Canada approval of ZORYVE Foam 0.3% - TipRanks
Canada approves new seborrheic dermatitis treatment - Investing.com
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - The Manila Times
Canada approves new seborrheic dermatitis treatment By Investing.com - Investing.com UK
A better buy-in window may exist right now for Arcutis Biotherapeutics Inc (ARQT) - SETE News
Wesbanco Bank Inc. Makes New Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
When (ARQT) Moves Investors should Listen - Stock Traders Daily
ARQT’s latest rating updates from top analysts. - Knox Daily
Examining Arcutis Biotherapeutics Inc (ARQT) stock is warranted - US Post News
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Update - MarketBeat
S&P 100 Index (OEX) QuotePress Release - The Globe and Mail
Stock Performance Spotlight: Arcutis Biotherapeutics Inc (ARQT) Ends the Day at 9.79, Up by 0.10 - The Dwinnex
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Millennium Management LLC - MarketBeat
Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments - Insider Monkey
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.6%Should You Sell? - MarketBeat
Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT) - Insider Monkey
AQR Capital Management LLC Has $2.39 Million Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Hsbc Holdings PLC Sells 492,187 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics director sells $92,616 in stock - Investing.com India
Arcutis Biotherapeutics director sells $92,616 in stock By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Arcutis with consistent target - Investing.com India
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Sells $37,287.25 in Stock - MarketBeat
Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com
Arcutis exec sells shares worth over $37k - Investing.com
Arcutis exec sells shares worth over $37k By Investing.com - Investing.com UK
Mizuho maintains Outperform on Arcutis with consistent target By Investing.com - Investing.com Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 6.5% Higher - MarketBeat
Perceptive Advisors LLC Purchases 808,500 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations - Dermatology Times
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):